NASDAQ
Arcutis already has its key drug approved for various diseases and concentrations. Sales are expanding rapidly, and Arcutis is positioned for growth....
Does Arcutis Biotherapeutics, Inc. (ARQT) have what it takes to be a top stock pick for momentum investors? Let's find out....
Arcutis today announced that Amit Munshi has been appointed to its BOD, and announced the retirement of founder and Board member Bhaskar Chaudhuri, PhD....
Arcutis Biotherapeutics has transitioned to profitability, driven by Zoryve's strong sales growth and market acceptance. Management projects Zoryve peak sales of $2.6B–$3.5B, far above Wall Street's $...
Investors need to pay close attention to ARQT stock based on the movements in the options market lately....
Arcutis aims to expand its market reach with new approvals. Management recently pleased the market with its sales guidance for Zoryve....
Arcutis Biotherapeutics (ARQT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues....
Campbell and CO Investment Adviser LLC trimmed its stake in Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) by 78.5% during the undefined quarter, according to its most recent disclosure with the Securit...
After reaching an important support level, Arcutis Biotherapeutics, Inc. (ARQT) could be a good stock pick from a technical perspective. ARQT surpassed resistance at the 20-day moving average, suggest...
FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5...
No price data available for this timeframe.